Suppression of skin lesions and SLE nephritis by increasing Treg in MRL/FAS lpr mice by administration of bee venom Apitoxin®
Abstract Background Apitoxin®, a drug based on bee venom was approved and released in Korea in 2003 as the ethical drug (ETC). It is well-known for its pain-relieving properties due to its potent anti-inflammatory effects. This raises the question of whether bee venom has benefits for other inflamma...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2025-03-01
|
| Серии: | Advances in Rheumatology |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1186/s42358-025-00448-5 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|